Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm,... von Ladenstein, Ruth, Prof, Pötschger, Ulrike, MSc, Pearson, Andrew D J, Prof, Brock, Penelope, MD, Luksch, Roberto, MD, Castel, Victoria, MD, Yaniv, Isaac, Prof, Papadakis, Vassilios, MD, Laureys, Geneviève, MD, Malis, Josef, MD, Balwierz, Walentyna, Prof, Ruud, Ellen, MD, Kogner, Per, Prof, Schroeder, Henrik, Prof, de Lacerda, Ana Forjaz, MD, Beck-Popovic, Maja, MD, Bician, Pavel, MD, Garami, Miklós, MD, Trahair, Toby, MD, Canete, Adela, MD, Ambros, Peter F, PhD, Holmes, Keith, MD, Gaze, Mark, MD, Schreier, Günter, PhD, Garaventa, Alberto, MD, Vassal, Gilles, Prof, Michon, Jean, MD, Valteau-Couanet, Dominique, MD

Volltext

Ethnic differences in the incidence of childhood cancer von Bician, Pavel, Mego, Michal

Volltext

RISK FACTORS IN HIGH RISK NEUROBLASTOMA PATIENTS OVER 5 YEARS: RESULTS FROM THE HR-NBL1/SIOPEN TRIAL von Ladenstein, R, Valteau-Couanet, D, Elliott, M, Luksch, R, Castel, V, Ash, S, Balwierz, W, Laureys, G, Beiske, K, Kogner, P, Papadakis, V, Beck-Popovic, M, Malis, J, Brok, JS, Vettenranta, K, Bician, P, Trahair, T, Chan, GCF, Owens, C, Lacerda, A, Sarnacki, S, Boterberg, T, Taschner-Mandl, S, Schleiermacher, G, Lode, H, Potschger, U

Volltext

Success of the HR-NBL/SIOPEN local control trial strategy in high risk neuroblastoma patients undergoing high dose therapy with peripheral stem cell transplantation von Ladenstein, R, Poetscher, U, Luksch, R, Castel, V, Yaniv, I, Papadakis, V, Laureys, G, Malis, J, Balwierz, W, Ruud, E, Kogner, P, Schroeder, H, de Lacerda, AF, Beck-Popovic, M, Bician, P, Garami, M, Trahair, T, Canete, A, Ambros, P, Holmes, K, Garaventa, A, Michon, J, Pearson, A, Valteau-Couanet, D, Gaze, M, Botterberg, T

Volltext

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial von Ladenstein, R. L., Poetschger, U., Luksch, R., Brock, P., Castel, V., Yaniv, I., Papadakis, V., Laureys, G., Malis, J., Balwierz, W., Ruud, E., Kogner, P., Schroeder, H., Forjaz De Lacerda, A., Beck Popovic, M., Bician, P., Garami, M., Trahair, T., Pearson, A. D., Valteau Couanet, D.

Volltext

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial von Ladenstein, R. L., Poetschger, U., Luksch, R., Brock, P., Castel, V., Yaniv, I., Papadakis, V., Laureys, G., Malis, J., Balwierz, W., Ruud, E., Kogner, P., Schroeder, H., Forjaz De Lacerda, A., Beck Popovic, M., Bician, P., Garami, M., Trahair, T., Pearson, A. D., Valteau Couanet, D.

Volltext

Early high-dose treatment: SCT results from the European High Risk Neuroblastoma Study von Ladenstein, R, Poetschger, U, Luksch, R, Brock, P, Castel, V, Yaniv, I, Papadakis, V, Laureys, G, Malis, J, Balwierz, W, Ruud, E, Kogner, P, Schroeder, H, de Lacerda, AMF, Beck-Popovic, M, Bician, P, Garami, M, Trahair, T, Valteau-Couanet, D

Volltext

Limits on Heavy Neutrinos at NA48/2 and NA62 von Bician, Lubos

Volltext